Why Compare Wegovy Doses vs Mounjaro Options?
Wegovy Doses vs Mounjaro: Mechanism Differences
Understanding how Wegovy doses vs Mounjaro work reveals fundamental differences in their approach to weight management. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your body's natural incretin hormone to reduce appetite and promote satiety after meals. This single-pathway mechanism has proven effective in the landmark STEP trials, where participants achieved significant weight loss alongside a reduced-calorie diet and increased physical activity.
Mounjaro takes a dual-pathway approach using tirzepatide, which activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors simultaneously. This combination targets multiple aspects of glucose regulation and appetite control, representing a newer therapeutic approach to weight management. When comparing Wegovy doses vs Mounjaro, this mechanistic difference may influence how each treatment works for individual patients, though both require careful dose escalation and ongoing medical supervision.
Wegovy vs Mounjaro Pricing Comparison
Transparent pricing helps you understand the investment required for each treatment option. Wegovy follows a five-step dose escalation: 0.25mg starter dose costs £79.99, progressing through 0.5mg (£94.99), 1mg (£99.99), 1.7mg (£139.99), to the maintenance 2.4mg dose at £209.99. Our Getting Started bundles like the Intro Duo (0.25mg & 0.5mg) provide two months' supply for £169.99, whilst the Ultimate Stability Trio offers three months of maintenance 2.4mg doses for £649.99.
Mounjaro's six-dose schedule starts at 2.5mg and escalates through 5mg, 7.5mg, 10mg, 12.5mg, to 15mg maximum strength. Both treatments require prescription-only access through our GPhC-registered pharmacy (#9012878), with new customers applying discount code FIRST40 and returning customers using DOSE25 at checkout. The total treatment cost varies based on individual tolerance, response, and maintenance dose requirements as determined by your prescriber.
Clinical Evidence for Wegovy Doses vs Mounjaro
The STEP clinical trial programme demonstrated that patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks in the STEP 1 trial, compared to 2.4% with placebo (Wilding et al., NEJM, 2021). The STEP 5 extension showed sustained weight loss of approximately 15.2% at two years, whilst the SELECT cardiovascular outcomes trial revealed a 20% reduction in major cardiovascular events.
Mounjaro's clinical evidence comes from the SURMOUNT trials, which evaluated tirzepatide specifically for weight management in adults without diabetes. These trials used different methodologies, patient populations, and endpoints compared to the STEP programme, making direct comparisons challenging. Both treatments demonstrated efficacy when used alongside lifestyle interventions, though individual responses vary significantly.
How Wegovy Works in Your Body
Wegovy's semaglutide ingredient functions as a GLP-1 receptor agonist, essentially mimicking a hormone your intestines naturally produce after eating. When you inject Wegovy once weekly using the pre-filled FlexTouch pen, it activates GLP-1 receptors in your brain's appetite control centres, specifically the hypothalamus. This activation sends signals that reduce hunger, increase feelings of fullness, and may diminish food cravings between meals. The medication also slows gastric emptying, meaning food stays in your stomach longer, contributing to prolonged satiety. Unlike quick-fix solutions, Wegovy works gradually as part of a comprehensive weight management programme that must include a reduced-calorie diet and increased physical activity.
Simple Ordering Process at EverydayMeds
Getting started with either Wegovy or Mounjaro involves our streamlined three-step process designed for busy lifestyles. Complete our confidential three-minute online clinical assessment, providing essential medical history and current health information for prescriber review. Our qualified prescribers typically review assessments within three working days, with express 24-hour review available for urgent requirements. Once approved, your prescription-only medicine ships via next-day delivery using specialist cold-chain packaging to maintain the required 2-8°C temperature throughout transit. All orders include detailed injection instructions, dose escalation guidance, and access to our clinical support team for ongoing questions.
Storage and Practical Considerations
Storage requirements reveal practical advantages when comparing Wegovy doses vs Mounjaro for travel and daily life. Both treatments require refrigeration at 2-8°C before first use, but Wegovy provides superior flexibility with up to six weeks storage at room temperature (below 30°C) once removed from the fridge. Mounjaro offers only 21 days at room temperature, potentially limiting travel plans or causing inconvenience during fridge malfunctions. Each Wegovy FlexTouch pen delivers four weekly doses, whilst injection technique remains consistent across all dose strengths. The mandatory dose escalation schedule helps minimise gastrointestinal side effects whilst allowing your body to adjust gradually to the medication's effects.
Wegovy vs Mounjaro: Dose Escalation Patterns
The dose escalation differences between Wegovy and Mounjaro reflect their distinct pharmacological profiles and tolerability requirements. Wegovy's five-step escalation spans 16 weeks before reaching maintenance, starting with 0.25mg for weeks 1-4, then 0.5mg (weeks 5-8), 1mg (weeks 9-12), 1.7mg (weeks 13-16), and finally 2.4mg maintenance from week 17 onwards. This gradual approach helps minimise common side effects like nausea, vomiting, and diarrhoea that can occur when starting GLP-1 treatments.
Mounjaro follows a six-step pattern with 2.5mg starting dose, escalating every four weeks through 5mg, 7.5mg, 10mg, 12.5mg, to maximum 15mg strength. Neither treatment allows dose skipping, and both require careful monitoring by healthcare professionals throughout the escalation period. The choice between these escalation patterns often depends on individual tolerance, response to treatment, and specific weight management goals discussed with your prescriber.
Making Your Choice: Expert Clinical Guidance
Both Wegovy and Mounjaro are available from EverydayMeds, giving you access to expert clinical guidance in choosing the most appropriate treatment for your circumstances. Your prescriber considers factors including medical history, current medications, previous weight loss attempts, and lifestyle factors when recommending between these prescription-only medicines. Our GPhC-registered pharmacy (#9012878) ensures you receive genuine, properly stored medication with comprehensive support throughout your weight management journey. Whether you start with Wegovy's proven GLP-1 pathway or explore Mounjaro's dual-receptor approach, both treatments require commitment to dietary changes and increased physical activity. Contact our clinical team to discuss which option aligns best with your health goals, budget considerations, and personal preferences for this important health investment.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
